Edgewell's Back-Half Religion Meets a New Cost Story
A 510-basis-point Q4 margin pop and a fresh 'broader transformation' cannot hide a 0.3% organic year, a six-month plant delay, and a lower cash-flow marker.
EPC · Earnings Call · 2026-11-12
Edgewell just posted its best quarterly margin in years and immediately asked investors to wait another six months for the proof. That is the tension in this report.The Quarter Was Strong. The Year Was Not.
The headline quarter was genuinely strong. Q4 organic sales rose 3.1%, adjusted gross margin expanded 510 basis points, adjusted EPS jumped to $0.78 from $0.52, and adjusted EBITDA nearly doubled to $76.8 million. Rod Little called fiscal '26 “a year of meaningful progress and change at Edgewell” — Rod Little, President and Chief Executive Officer · 2026-11-12, and Fran Weissman hammered the margin point: “Adjusted gross margin increased 510 basis points compared with the prior year” — Francesca Weissman, Chief Financial Officer · 2026-11-12. The market has noticed: EPC is up 10.7% over the last 90 trading days and sits within 3.1% of its 90-day high.But the full year tells a quieter story. Organic sales grew only 0.3%, adjusted operating profit fell 7%, and adjusted operating margin was 8.1%, down 70 basis points. The last filed quarter showed revenue of $570 million, down 9% year over year, gross margin of 42.5%, and operating margin of 4.4%. This is not yet a growth company; it is a margin-recovery company with a growth story attached.
The New Label: Broader Transformation
The fresh theme on the call was not tariffs or the Feminine Care divestiture. It was a broader transformation of the operating model. Management described simplifying structures, strengthening procurement, sharpening resource allocation, and using AI-enabled capabilities to create a structurally lower cost base. At the same time, brand building and commercial investment are now top-ranked company themes. They are no longer side notes to cost cuts; they are the plan. A&P is guided to about 13% of sales, up 80 basis points, with a step-up to roughly 14% in Q1. Little argued the company is spending three points of sales more on marketing and advertising than in fiscal '24.That is a real shift in emphasis, and it is backed by better brand evidence: Hawaiian Tropic gained about 280 basis points of share, Cremo grew more than 50%, and branded Wet Shave accelerated. The company also held or grew value share in roughly 70% of country-category combinations. For a name that has spent years talking about tariff mitigation and stranded costs, this is a more attractive vocabulary.
Still a Back-Half Story
The problem is timing. Fiscal '27 guidance calls for organic sales growth of 1% to 3%, adjusted operating profit growth of about 10%, adjusted EPS of $1.85 to $2.15, and adjusted EBITDA of $250 million to $270 million. But Q1 organic sales are guided flat to down 1%, Q1 adjusted EPS is expected below the prior year, and two-thirds of EBITDA and about 80% of EPS are back-half weighted. This is the same shape investors have seen before. In August, Little said “we have line of sight for the second half to that” — Rod Little, President and Chief Executive Officer · 2026-08-05, referring to the second-half inflection. In the current call, he acknowledged Q1 is “really the quarter that's most impacted” — Rod Little, President and Chief Executive Officer · 2026-11-12 by the private-label supply constraint.That is the credibility gap. The company did deliver the Q4 acceleration it promised, but only after guiding down through the year. Now it is asking for another back-half delivery while absorbing elevated inflation and the expiration of TSA income. Weissman sized the inflation at about 300 basis points, offset by more than 250 basis points of productivity and volume absorption. The math works on paper; the execution risk is in the second half.
The Self-Inflicted Supply Constraint
The Wet Shave manufacturing consolidation is the most important company-specific issue. Four plants are being consolidated into one greenfield site. Little said the project is roughly halfway done, but the timeline has slipped: “the consolidation timeline has shifted by about six months compared with our original plan, and we now expect the associated savings to begin in fiscal '28” — Rod Little, President and Chief Executive Officer · 2026-11-12. In fiscal '26, private label shave fell about 10% because of the supply constraint, while branded shave grew about 2%. Q1 fiscal '27 is expected to be the trough, with private label returning to growth in the second half.That is an unusually candid admission. It also conflicts with the prior call's tone, when management said the supply issue was largely behind it and that it had “now solved much of that from a production capacity standpoint” — Rod Little, President and Chief Executive Officer · 2026-08-05. The delay pushes the cost unlock into FY28 and leaves the private-label drag in the base for another year.We don't love where we are, but we feel good about where we are.
The Cash-Flow Marker Moved
The balance sheet is the other tension. Effective net cash was -$853 million at the last filed quarter-end, and interest coverage was just 1.5x. Management targets adjusted net debt leverage of 3.4x and says deleveraging remains the near-term priority. That is why the cash-flow guide matters.In February, Little put a marker down: “we ought to be at a $150 million plus free cash flow as we look to next year” — Rod Little, President and Chief Executive Officer · 2026-02-09. The current FY27 guide is $100 million to $120 million, as Weissman stated: “Adjusted free cash flow for the year is expected to be in the range of $100 million to $120 million” — Francesca Weissman, Chief Financial Officer · 2026-11-12. Some of that gap is restructuring cash costs and working capital, but it is still a lower marker than the one investors were given. With price to free cash flow at 38.7x and price to revenue at 0.6x, the equity is pricing a successful transformation, not the current cash generation.
What Would Make It Real
The bull case is straightforward: Q4 proves the brand investment can work, the transformation savings offset remaining stranded costs, private label recovers in the second half, and the Wet Shave plant becomes a FY28 cost unlock. Gross margin is guided up about 60 basis points despite roughly 300 basis points of inflation; SG&A is guided down 90 basis points; A&P rises but should build brand equity. If that lands, Edgewell can grow earnings faster than sales and start to delever.The bear case is just as clear: this is the fourth consecutive year where the payoff is back-half weighted; the plant delay is self-inflicted; the TSA cliff removes $0.17 of EPS; and the cash-flow marker has already moved lower. The company's own history shows how hard it is to break the pattern. The stock is up 10.7% in 90 days, but it is still 73% below its 2015 peak. That is not a market that believes the transformation yet; it is a market willing to rent the story for a quarter.
The tell will be Q2 and Q3 fiscal '27, not the Q4 print. If private label returns to growth and the transformation shows up in SG&A while A&P holds, the new label will have earned itself. If not, Edgewell has simply renamed cost-cutting and pushed the payoff out again.